)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
PExA
PExA (PEXA) investor relations material
PExA Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Q3 revenue was SEK 6,775; the nine-month period recorded SEK 1.20m, while net losses narrowed YoY in both periods. Cash rose to SEK 23.6m after July equity issues.
Two studies strengthened scientific validation: Australian research found proteins from PExA samples also present in invasive lung lavage, and Karolinska researchers measured virus-specific antibodies in small-airway samples.
Financial highlights
Q3 net sales were SEK 6,775 vs SEK 44,489 YoY; 9M net sales were SEK 1,195,334 vs SEK 357,069.
Q3 net loss was SEK 1.53m vs SEK 2.57m; 9M net loss was SEK 3.73m vs SEK 7.14m. Q3 operating loss was SEK 1.57m vs SEK 2.58m.
EPS was -SEK 0.01 in Q3 vs -SEK 0.04, and -SEK 0.03 for 9M vs -SEK 0.11.
Q3 operating cash flow was SEK 160,616 vs -SEK 2.03m; total Q3 cash flow was SEK 22.82m vs SEK 6.37m.
Outlook and guidance
Strategy focuses on Biomarker Discovery, pharmacokinetics/pharmacodynamics (PK/PD), and future Diagnostics applications; no quantitative financial targets were stated.
A pharma agreement worth ~SEK 7.5m covers rental of ten systems for an international pulmonary-fibrosis study; €325,000 was invoiced and received, with revenue recognized over the rental period.
Management expects stronger scientific evidence, broader international use, and new applications to support commercial opportunities in biomarker research, drug development, vaccine research, and future diagnostics.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PExA
- Major pharma contract and capital raises drive improved financial outlook and global expansion.PEXA
Q2 2026 - Q1 2026 saw strong sales growth, improved results, and key research orders, but more funding is needed.PEXAQ1 2026
- Strategic refocus on lung cancer diagnostics, narrowed losses, and improved cash position.PEXAQ4 2025
- Q3 revenue up 41%, rights issue secures 9.9 MSEK for diagnostic expansion.PEXAQ3 2025
- Revenue up, losses narrowed, and a guaranteed rights issue launched to fund clinical expansion.PEXAQ2 2025
- Sales and earnings fell, but strong equity and new funding support global expansion and R&D.PEXAQ3 2024
- Revenue fell and losses increased, but new funding and scientific milestones support future growth.PEXAQ2 2024
- No Q1 revenue as PEXA pivots to clinical focus; funding needed amid strong tech validation.PEXAQ1 2025
- Revenue declined and losses deepened, but scientific and market momentum remain strong.PEXAQ4 2024
Next PExA earnings date
Q4 202619 Feb, 2027
PExA
Next PExA earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PExA AB is a Sweden-based biotechnology company focused on developing innovative solutions for respiratory research. The company specializes in equipment and methods for non-invasive sampling of biomarkers from the small airways, enabling advancements in the understanding and diagnosis of respiratory diseases. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Spotlight Stock Market.